The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
about
Effectiveness of second generation antipsychotics: a systematic review of randomized trialsClozapine: a review of clinical practice guidelines and prescribing trendsSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewOff-label use of sodium valproate for schizophreniaThe Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP studyConformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy.Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsA conditional model of evidence-based decision makingEffectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trialSchizophrenia: current concepts and approaches to patient careSchizophrenia: overview and treatment options.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patientsGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.Clinical potential of lurasidone in the management of schizophrenia.The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, BrazilPolypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.Quantifying clinical relevance in the treatment of schizophrenia.Effect of pharmacist intervention on physician prescribing in patients with chronic schizophrenia: a descriptive pre/post study.Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year ComparisonHospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand.The effect of providing patient-specific electronically monitored antipsychotic medication adherence results on the treatment planning of prescribers of outpatients with schizophrenia.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceAripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital.Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient HospitalsTreatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national studyAntipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysisPrescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams.Second-generation antipsychotic discontinuation in first episode psychosis: an updated review.Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia.Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities.Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention.
P2860
Q21260262-137C49D7-B040-45E9-AFEC-D0AA8A508034Q21260307-47B8F396-AFE5-4E75-B208-313ED3F99154Q26752965-FBA34089-BE26-4FA9-9748-742D6E71167DQ28079821-769469D3-0C63-4DD9-A53B-DB365CB4B8F5Q28541404-2D6256E1-8AE0-47FE-81BF-5F1DB5251B95Q30492614-BCAC1DD4-7218-4A57-AD51-4A69D789ABD5Q30627430-D55F6A5C-5D3C-48C1-914A-88A13F622FC3Q33455799-DD0A4F6E-4632-4A18-913A-5DAAA96B7F14Q33464064-A762B1B9-B217-4EAD-9F82-A2A7A95DA225Q33545458-39498B1A-2D00-462D-9469-2C51862DFAD8Q33566124-1D125036-4FFF-421B-862D-968D1BD9C240Q33775810-49AE8FAD-9995-4232-BA93-4BEE4A2C1025Q33914295-C0D6713D-D8AE-45ED-ABFE-1FF5FBA1F4DEQ33932520-8A68E71F-9342-46A6-A71E-963CF57B62A6Q34154951-A38C908A-60C8-4FE0-9342-BD3723DB749DQ34418847-11478287-134C-471B-A216-B32AC8BBF6F3Q34661651-D440A456-13EF-4E89-BAC4-6A01E30F85F5Q35073474-FB4F9E98-25D5-47DD-9E8F-B4C4C80CEF7DQ35093143-2F044696-F871-4384-8F95-66C59BE1AD34Q35324015-4CFC872B-44AE-4EFB-B511-B0088E5A7035Q35608522-6F5D91E9-07C6-47B7-B02C-1665DF1C8A9DQ35819467-41509700-63D4-4F14-946E-2C2661C35D57Q36000102-A0994C70-1CC3-401C-B9FC-6600CAFE1CB3Q36325431-E2137CFF-DF25-4243-B6CC-3BCAC28DB51EQ36872731-8E74DE5A-04A6-4755-9BEB-A52B68ABB6F3Q36881371-1FD7A17A-88C5-4F85-95B9-95C766EC0250Q37029622-80DB24C7-EEC4-488B-AE7D-9B112E7FCE76Q37078928-BE44284C-8594-4EF2-B25A-FAAF88E47160Q37116547-526D1717-29C8-4A7B-8D83-E2298540D8E8Q37220015-EEDAD9C9-B1F8-4CED-8DF7-895C85F8BEABQ37609168-415A7AAB-D064-40CA-9F24-E56BD92FD02EQ37705255-DE781520-A617-4C31-A6C0-3A88235DA83EQ38083513-E1504CB5-62B9-4BEC-AC19-0070DB8375C0Q38625817-5488DB49-BD3F-41C6-88FC-21261A7A5AAEQ38851123-E7AE6269-4448-48A2-B92D-2D8C72AAD369Q39128141-7ADE8684-E849-41D2-B732-B09D316517B1Q41656775-0F20398D-14E6-4E50-9C65-4FFB5A2D271FQ41889293-C9959636-9EF9-4AD2-B4B2-A51F8FE16B5DQ42180852-88250183-57FC-4CEA-A66E-CC8DD54C9AECQ42692847-4CAC445E-EAC6-4D92-8C6E-334D29795523
P2860
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The Texas Medication Algorithm ...... or schizophrenia: 2006 update.
@ast
The Texas Medication Algorithm ...... or schizophrenia: 2006 update.
@en
The Texas Medication Algorithm ...... or schizophrenia: 2006 update.
@nl
type
label
The Texas Medication Algorithm ...... or schizophrenia: 2006 update.
@ast
The Texas Medication Algorithm ...... or schizophrenia: 2006 update.
@en
The Texas Medication Algorithm ...... or schizophrenia: 2006 update.
@nl
prefLabel
The Texas Medication Algorithm ...... or schizophrenia: 2006 update.
@ast
The Texas Medication Algorithm ...... or schizophrenia: 2006 update.
@en
The Texas Medication Algorithm ...... or schizophrenia: 2006 update.
@nl
P2093
P356
P1476
The Texas Medication Algorithm ...... for schizophrenia: 2006 update
@en
P2093
Alexander L Miller
Del D Miller
Delbert G Robinson
John A Chiles
Joseph P McEvoy
M Lynn Crismon
Nina R Schooler
Peter F Buckley
Robert R Conley
Robert W Buchanan
P304
P356
10.4088/JCP.V68N1115
P577
2007-11-01T00:00:00Z